dbacp06293
General Description
Peptide name : Tetramer of peptide-paclitaxel conjugate
Source/Organism : Synthetic peptide paclitaxel conjugate
Linear/Cyclic : Linear
Chirality : L
Sequence Information
Sequence : (K-Aib-C(CH2CO-2'-Pac))4
Peptide length: Not available
C-terminal modification: Linear
N-terminal modification : Amidation
Non-natural peptide information: Aib : 1-amino-isobutyric acid ,Pac : Paclitaxel
Activity Information
Assay type : MTT/MTS assay
Assay time : 24h
Activity : IC50 : 0.96 nM
Cell line : HeLa
Cancer type : Cervical cancer
Other activity : Not found
Physicochemical Properties
Amino Acid Composition Bar Chart : Not available
Molecular mass : Not available
Aliphatic index : Not available
Instability index : Not available
Hydrophobicity (GRAVY) : Not available
Isoelectric point : Not available
Charge (pH 7) : Not available
Aromaticity : Not available
Molar extinction coefficient (cysteine, cystine): Not available
Hydrophobic/hydrophilic ratio : Not available
hydrophobic moment : Not available
Missing amino acid : Not available
Most occurring amino acid : Not available
Most occurring amino acid frequency : Not available
Least occurring amino acid : Not available
Least occurring amino acid frequency : Not available
Structural Information
3D-structure: Not available
Secondary structure fraction (Helix, Turn, Sheet): Not available
SMILES Notation: Not available
Secondary Structure :
| Method | Prediction |
|---|---|
| GOR | Not available |
| Chou-Fasman (CF) | Not available |
| Neural Network (NN) | Not available |
| Joint/Consensus | Not available |
Molecular Descriptors and ADMET Properties
Molecular descriptors: Not available
ADMET properties: Not available
Cross Referencing Databases databases
Pubmed Id : 17787026, .
Uniprot : Not available
CancerPPD : Click here
ApIAPDB : Not available
Reference
1 : Papas S, et al. Synthesis and antitumor activity of peptide-paclitaxel conjugates. J Pept Sci. 2007; 13:662-71. doi: 10.1002/psc.899
Literature
Paper title : Synthesis and antitumor activity of peptide-paclitaxel conjugates.
Doi : https://doi.org/10.1002/psc.899
Abstract : Paclitaxel (Pac) is the most important anticancer drug used mainly in treatment of breast, lung, and ovarian cancer and is being investigated for use as a single agent for treatment of lung cancer, advanced head and neck cancers, and adenocarcinomas of the upper gastrointestinal tract. In this work, we present the synthesis of five 2'-paclitaxel-substituted analogs in which paclitaxel was covalently bound to peptides or as multiple copies to synthetic carriers. Ac-Cys(CH(2)CO-2'-Pac)-Arg-Gly-Asp-Arg-NH(2), Folyl-Cys(CH(2)CO-2'-Pac)-Arg-Gly-Asp-Ser-NH(2), Ac-[Lys-Aib-Cys(CH(2)CO-2'-Pac)](2)-NH(2), Ac-[Lys-Aib-Cys(CH(2)CO-2'-Pac)](3)-NH(2) and Ac-[Lys-Aib-Cys(CH(2)CO-2'-Pac)](4)-NH(2) were synthesized using 2'-halogeno-acetylated paclitaxel derivatives. Paclitaxel conjugates showed greater solubility in water than paclitaxel and inhibited the proliferation of human breast, prostate, and cervical cancer cell lines. Although all synthesized compounds had an antiproliferative activity, the Ac-[Lys-Aib-Cys(CH(2)CO-2'-Pac)](4)-NH(2) derivative showed improved biological activity in comparison with paclitaxel in cervical and prostate human cancer cells.